首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1148461

糖尿病治療藥的全球市場 - 預測(2022年～2027年)

Global Diabetes Care Drugs Market - Forecasts from 2022 to 2027

出版日期: 2022年10月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 138 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球糖尿病治療藥的市場規模預測將從2020年的599億3,600萬美元，到2027年前達到1,038億5,100萬美元，以年複合成長率8.17％成長。兒童的第一型糖尿病和成人的第二型糖尿病的流行，正在推動需求激增。

本報告提供全球糖尿病治療藥市場相關調查分析，提供市場動態，市場區隔分析，地區分析，企業簡介等資訊。

簡介
北美
- 美國
- 加拿大
- 墨西哥
南美
- 巴西
- 阿根廷
- 其他
歐洲
- 英國
- 德國
- 法國
- 西班牙
- 義大利
- 其他
中東·非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 其他
亞太地區
- 日本
- 中國
- 印度
- 韓國
- 台灣
- 泰國
- 印尼
- 其他

第10章競爭環境與分析

主要企業與策略的分析
新興企業和市場收益性
合併·收購·協定·聯盟
供應商的競爭力矩陣

第11章企業簡介

AstraZeneca
Eli Lilly and Company
Sanofi
Novo Nordisk A/S
Mankind Pharma
Glenmark Pharmaceuticals Ltd.
Natco Pharma Litmited

簡介目錄

Product Code: KSI061613632

The global diabetes care drugs market is projected to grow at a CAGR of 8.17% to reach US$103.851 billion by 2027, from US$59.936 billion in 2020.

The rising prevalence of type-1 in children and type-2 diabetes in adults is causing a surge in demand.

According to WHO, diabetes is a chronic disease that is caused by a high level of glucose present in the blood. It can lead to severe damage to organs such as the heart, blood vessels, and kidneys, among others. Diabetes type 2 is considered the most common type of diabetes and affects adults when the body becomes resistant to insulin.

On the other hand, type 1 diabetes is dependent on insulin and is caused when the pancreas produces very little insulin. The number of individuals suffering from diabetes has risen from 108 million to 422 million in 2014. Moreover, the prevalence of diabetes in individuals over 18 years, which was previously found to be 4.7% in 1980, has surged to 8.5% in 2014.

In addition, diabetes can be treated if a healthy diet is followed and a good amount of exercise and strict recommendation of the doctor is followed. On the other hand, persons suffering from diabetes are actively demanding diabetes care drugs to keep their condition in check, and this is leading to market growth.

A growing proportion of the geriatric population is driving the market growth.

One of the major factors of the rise in demand for diabetic care drugs from geriatric individuals is the fact that during older age, the immune system and the endocrine system, among the other functions of the body, are not up to their full potential, which makes pancreas little weaker and thus making them prone to diabetes. Therefore, this is causing the elderly population to demand diabetic drugs.

Product offerings, acquisitions, and launches by Major Market Players in the diabetes care drugs market space

The involvement and participation of the market player are increasing to cater to the demand of the end-user more effectively. They are bringing advancement and enhancements by the launch of new products and partnership agreements with better compositions, which are more effective, thus contributing to improving their market position and bolstering the market growth further.

Some of the examples of product launches and partnership agreements are as follows:

In May 2022, the new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist MounjaroTM (tirzepatide) injection from Eli Lilly and Company has been given FDA approval. It is indicated as a supplement to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro is not recommended for usage in people with type 1 diabetes mellitus and has not been evaluated in individuals with a history of pancreatitis.
In February 2022, Suganon® (evogliptin), a novel treatment for people with type 2 diabetes, is being introduced in Latin America by Eurofarma. New DPP-4 enzyme inhibitor Suganon® (evogliptin) provides the advantages of simple administration and low possibility for drug interactions, delivering better convenience and safety for prescribers and type 2 diabetic patients.
Recently in April 2020, Natco Pharma, which is a company dealing in the provision of different types of drugs and is based in India, announced that they had launched a new product under the brand name "Danpat."The product is an affordable and low-cost copy of the drug called "Farxiga," a drug by the company AstraZeneca. In addition, this drug, which has been launched, is lower in concentration than Farxiga and will be available in 5mg and 10mg.
In January 2020, Eli Lilly and Company announced their latest triple combination drug called "Trijardy XR," which consists of three diabetes type-2 medications. The tablet consists of "empagliflozin," "linagliptin," and an extended-release drug called "metformin hydrochloride" has been approved for usage by the U.S. Food and Drug Administration. It will be available in four different dosages and is indicated to be used once daily, together with a healthy and complete diet and exercise.
In September 2019, a new medication called "Ryebelsus" (semaglitude), developed by the company Novo Novodisk was approved by the U.S. Food and Drug Administration. The medication has been developed for the glucagon-like peptide (GLP-1) receptor protein treatment and is approved for use in the United States; that is the first oral drug. It can improve control over the blood sugar in adult patients suffering from type-2 diabetes and is a non-insulin type treatment.
In December 2019, Mankind Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd. announced that they hadentered into a partnership agreement to co-market the anti-diabetic drug called "remogliflozin etabonate" in India. Under this agreement, Mankind pharma will market the drug under its trademark. On the other hand, Glenmark will contribute to the agreement by manufacturing and supplying the drug to the company.

The Asia Pacific region is poised to show a considerable growth rate over the forecast period owing to increasing healthcare sector spending, and the North American region is expected to hold a noteworthy share over the forecast period.

The North American region is expected to hold a noteworthy share over the forecast period owing to the fact that the healthcare sector in countries such as the US is well developed. In conjunction, there is a good number of investments in the R&D of better drugs and medicines in order to control diabetes type 2 effectively pharmaceutical companies.

The Asia Pacific region is poised to show a considerable growth rate over the forecast period owing to the increasing number of efforts being made and the initiatives being taken by the government by pumping investments into the healthcare sector in order to promote the development of better drugs for diseases such as diabetes in India. In addition, there is increasing involvement of market players such as Mankind and Glenmark to manufacture and distribute diabetes-related drugs in countries such as India.

Impact of the COVID-19 pandemic

The COVID-19 pandemic led to a significant slowdown in the economy, owing to the suspension of industrial processes and activities. The diabetes care drugs market initially faced a decrease in revenue due to the disruptions in supply and production lines. However, the market was soon met by a substantial increase in demand, owing to the increasing instances of diabetes among people. Government initiatives and programs to help people access essential healthcare treatments and medicines also help in replenishing the market demand. Moreover, as most countries have started to lift COVID-19 protocols, the market is expected to report an increase in demand, owing to the increasing instances of diabetes and obesity-related disorders. According to the National Diabetes Statistics 2022, the CDC estimates about 130 million adults to be living with diabetes in the United States.

Segmentation:

By Condition

Diabetes Type 1

Diabetes Type 2

By Drug Class

Insulin

Rapid Acting
Short-Acting
Long Acting
Others

Sulfonylureas

Meglitinides

Thiazolidinedione

Others

By Delivery Method

Vials

Pens

Tablets

By End-User

Hospitals and Clinics

Household

By Geography

North America

USA
Canada
Mexico

South America

Brazil
Argentina
Others

Europe

UK
Germany
France
Spain
Italy
Others

Middle East and Africa

Saudi Arabia
UAE
Israel
Others

Asia Pacific

Japan
China
India
South Korea
Taiwan
Thailand
Indonesia
Other

1. Introduction

1.1. Market Definition
1.2. Market Segmentation

2. Research Methodology

2.1. Research Data
2.2. Assumptions

3. Executive Summary

3.1. Research Highlights

4. Market Dynamics

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Global Diabetes Care Drugs Market Analysis, by Condition

5.1. Introduction
5.2. Diabetes Type 1
5.3. Diabetes Type 2

6. Global Diabetes Care Drugs Market Analysis, by Drug Class

6.1. Introduction
6.2. Insulin
- 6.2.1. Rapid Acting
- 6.2.2. Short-Acting
- 6.2.3. Long-Acting
- 6.2.4. Others
6.3. Sulfonylureas
6.4. Meglitinides
6.5. Thiazolidinedione
6.6. Others

7. Global Diabetes Care Drugs Market Analysis, by Delivery Method

7.1. Introduction
7.2. Vials
7.3. Pens
7.4. Tablets

8. Global Diabetes Care Drugs Market Analysis, by End-User

8.1. Introduction
8.2. Hospitals and Clinics
8.3. Household

9. Global Diabetes Care Drugs Market Analysis, by Geography

9.1. Introduction
9.2. North America
- 9.2.1. United States
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. UK
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Spain
- 9.4.5. Italy
- 9.4.6. Others
9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. United Arab Emirates
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Taiwan
- 9.6.6. Thailand
- 9.6.7. Indonesia
- 9.6.8. Others